NEW OR RETURNING USERS: SIGN IN  |   UPDATE PROFILE  |   CME/CE TRACKER    



  

Managed Care

Keeping Pace with Targeted Therapies
in Breast Cancer:

Highlights from the 2006 ASCO Annual Meeting
This CME/CE activity has reached its termination date and no longer offers continuing education credit. Please note that expired CME/CE activities may not contain the most up-to-date information available.

Click here to view our current activities in Managed Care.

Keeping Pace with Targeted Therapies
in Breast Cancer:
Highlights from the 2006 ASCO Annual Meeting
Free 1-hour CME/CE Webcast Featuring Expert Faculty

You may also be interested in The Advanced Certificate Program: Breast Cancer Management. This yearlong CME/CE program offers clinicians current cutting-edge information targeting the management of breast cancer. Learn more...
or


This program, featuring highlights of presentations from the 2006 Annual Meeting of the American Society of Clinical Oncology (ASCO), describes exciting new developments in the use of targeted therapy in metastatic and early stage disease, including expanded use of current agents and promising new drugs.

CHAIR
CHAIR

Harold J. Burstein, MD, PhD
Assistant Professor of Medicine
Department of Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts


FACULTY
Francisco J. Esteva, MD, PhD
Associate Professor of Medicine
Breast Medical Oncology
The University of Texas M.D. Anderson Cancer Center
Houston, Texas

Maureen Major, RN, MS
Clinical Nurse Specialist
Department of Nursing
Memorial Sloan-Kettering Cancer Center
New York, New York
top

TARGET AUDIENCE
This activity is designed for medical directors, pharmacy directors, and nurse case managers who provide care for patients with breast cancer.

ACTIVITY GOAL
The goal of this CME/CE activity is to provide state-of-the-science highlights and associated information from ASCO to educate managed care audiences on innovations in targeted therapies for the treatment of breast cancer.

LEARNING OBJECTIVES
  • Assess the impact of targeted therapies on breast cancer, utilizing knowledge of the mechanism of action of these agents on cancer growth.

  • Analyze the impact of targeted therapies on breast cancer patient outcomes based on their effect on overall survival and progression-free survival.

  • Using knowledge of efficacy and safety data of emerging biologics and targeted therapies, integrate these agents into customized treatment regimens that enhance compliance, survival, and quality of life for breast cancer patients.
top

CME INFORMATION

STATEMENT OF ACCREDITATION: PHYSICIANS
Projects In Knowledge is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION
Projects In Knowledge designates this educational activity for a maximum of 1.0 AMA PRA Category 1 CreditTM Physicians should only claim credit commensurate with the extent of their participation in the activity.

This activity has been planned and implemented as an independent CME activity in accordance with the ACCME Essential Areas and Policies.

CE INFORMATION: NURSES
This activity has been approved by the American Association of Critical-Care Nurses (AACN) for 1.0 contact hour. Provider #00012705.

CE INFORMATION: PHARMACISTS
Projects In Knowledge is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

This activity has been planned and implemented in accordance with the ACPE Criteria for Quality and Interpretive Guidelines. The ACPE Universal Program Number assigned to the live Q&A program is 052-000-06-020-L01, and to the on-demand program is 052-000-06-020-H01. Either number provides 1 contact hour (0.1 CEU).

Contract for Mutual Responsibility in CME/CE

Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.
For more information on the contract, click here.

top

DISCLOSURE INFORMATION
The Disclosure Policy of Projects In Knowledge requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials.
For complete prescribing information on the products discussed during this CME activity, please see your current Physicians' Desk Reference (PDR).

Harold J. Burstein, MD, PhD, has received grant/research support from and is on the speakers bureau of Genentech, Inc. Dr. Burstein has disclosed that he will reference the unlabeled or unapproved use of Phase III data on trastuzumab.

Francisco J. Esteva, MD, PhD, has received grant/research support from GlaxoSmithKline and Novartis. Dr. Esteva has disclosed that he will reference the unlabeled or unapproved use of adjuvant trastuzumab and lapatinib for metastatic breast cancer.

Maureen Major, RN, MS, is on the speakers bureau of Abraxis Oncology, Amgen Inc, Genentech, Inc, MGI Pharma, and Pfizer Inc. Ms. Major has disclosed that she will reference the unlabeled or unapproved use of bevacizumab, lapitinib, and trastuzumab.

Peer Reviewer has disclosed no significant relationships.

Projects In Knowledge's staff members have no significant relationships to disclose.

Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.

The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.

This CME/CE activity is provided by Projects In Knowledge solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.

Click here for TECHNICAL REQUIREMENTS


This independent CME activity is supported by an educational grant from
Genentech, Inc.

top

1773

 

 

Program Information

Faculty
Target Audience
Activity Goal
Learning Objectives
CME Information
Disclosure Information
Technical Requirements


By clicking below, I certify that I have read the accompanying CME/CE and disclosure information and am ready to continue to this activity.

Release Date: September 20, 2006.

Termination Date: September 20, 2007.

Estimated Time for Completion of this Activity: 1.0 hour.



Recommend this page
Recommend this to a colleague


This independent CME/CE activity is supported by an educational grant from Genentech, Inc.




ABOUT US CONTACT US CONTRACT DIRECTIONS PRIVACY POLICY RESOURCES
Copyright © 1997-2008, Projects In Knowledge, Inc. All rights reserved.
PROJECTS IN KNOWLEDGE • Overlook at Great Notch • 150 Clove Road, 10th Floor • Little Falls, New Jersey 07424 (973) 890-8988